Background In familial hypercholesterolemia (FH), low-density lipoprotein-cholesterol (LDL-C)-lowering therapy is important to avoid predisposition to coronary artery disease. This study investigated the advantages of combined therapy with atorvastatin and colestimide vs intensive monotherapy with atorvastatin.
amilial hypercholesterolemia (FH) is a genetically defined low-density lipoprotein (LDL) receptor abnormality characterized by LDL-hypercholesterolemia, tendinous xanthoma and premature coronary atherosclerosis. [1] [2] [3] Patients with FH are hypercholesterolemic from birth, so the incidence of coronary artery disease (CAD) is extremely high; approximately 85% of males and 50% of females suffer a coronary event before the age of 65 if they do not receive treatment. 2, 3 The number of homozygous patients is rare (1 in every 1 million people), but the number of heterozygous patients is extremely high (1 in every 500 people), which makes the disease one of the most frequent monogenic hereditary disorders in the general population.
As non-pharmacological therapy for FH, LDL-apheresis has been used as an absolute indication for homozygous and a relative indication for heterozygous patients with CAD. 4 The most important feature of LDL-apheresis is the removal of plasma LDL in an unlimited volume, if it can be used continuously. Thus, we can reduce plasma LDL levels in hypercholesterolemic patients to a targeted level. In particular, FH patients with CAD should be considered for LDLapheresis, because the target level is very low for such patients and apheresis can achieve very low levels of LDLcholesterol (C). However, because this therapy needs extracorporeal circulation and is expensive, it is not available for the entire FH population. Drug treatment in heterozygous patients includes high doses of HMG-CoA reductase inhibitors alone 5, 6 or in combination with anion-exchange resins and other drugs, 7, 8 but it has proved difficult to keep the LDL-C level below 100 mg/dl (2.6 mmol/L). 8, 9 One of the lipid-lowering agents used in the current study, atorvastatin, has been reported as effective for lipid management in not only typical hypercholesterolemia patients, but also patients with refractory hypercholesterolemia, including those with FH and those with a history of CAD who require strict cholesterol management, [10] [11] [12] because it has a potent lipid-lowering action and a safety profile equivalent to that of conventional statins. 13 Atorvastatin is the drug of first choice for early-stage treatment of patients with refractory hypercholesterolemia, including FH. When the target level cannot be achieved using the standard dose (10 mg/day in Japan), double the normal dose is administered.
Anion-exchange resins, which are another type of cholesterol-lowering drug, lower LDL-C by adsorbing bile acid in the intestinal tract and expelling it in the feces. 14 Because their mechanism of action differs completely from that of statins, an add-on effect is hoped for upon co-administration to FH patients. Witztum et al reported that co-administration of lovastatin and colestipol to FH patients was superior to co-administration of lovastatin and probucol. 15 In addition, Heinonen et al reported that a combination of atorvastatin and colestipol was effective. 16 In practice, it is often difficult to lower cholesterol to the target level in cases of FH and other types of refractory hypercholesterolemia, even with double the standard dose of atorvastatin, and therefore we have to consider combining drugs for the next stage of treatment. In other words, we need to decide whether we should increase the dose of atorvastatin to 4-fold the standard dose or add an anion-exchange resin. Co-administration of statins with colestimide, a new anion-exchange resin, resulted in additive efficacy on statin in Japanese FH patients; 17 however, to our knowledge, there has not been a comparative study between 4-fold atorvastatin dosage and its combination with colestimide. Therefore, in this study, in order to select the next step for refractory FH therapy, we compared the cholesterol-lowering action, adverse reactions and tolerability of intensive atorvastatin monotherapy with those of combined therapy with atorvastatin and colestimide, using a cross-over design in patients with refractory heterozygous FH.
Methods
This open-label randomized cross-over single center trial was designed and monitored in accordance with the ethics and principles of Good Clinical Practice and the Declaration of Helsinki. An institutional review board approved the protocol before the trial started, and all participants gave written informed consent.
Subjects
The study subjects visited the Hospital of the University of Occupational and Environmental Health as outpatients between October and December 2002 for diagnosis and treatment of hypercholesterolemia. Heterozygous FH was determined by the following criteria: (1) primary hypercholesterolemia (total cholesterol ≥5.9 mmol/L and <12.9 mmol/L) and tendon xanthoma or (2) primary hypercholesterolemia with a definite diagnosis of FH in any firstdegree relative. 2 Twenty-four consecutive heterozygous FH patients (age: 57.7±13.4 years; 7 males, 17 females) were enrolled. As an initial treatment, the patients were given 20 mg/day atorvastatin for 3 months or longer on an outpatient basis, and those who did not subsequently satisfy the criteria in the Japan Atherosclerosis Society's Guidelines for the Diagnosis and Treatment of Atherosclerotic Cardiovascular Diseases 18 became the final subjects. The initial treatment was deemed to be effective when the LDL-C in patients with no history of CAD was less than 3.6 mmol/L (140 mg/dl) or 3.1 mmol/L (120 mg/ml) and when that in patients with a history of CAD was less than 2.6 mmol/L (100 mg/dl). Based on these criteria, 17 of the 24 patients did not achieve the target level and became the final subjects (age: 54.1±13.0 years; 5 males, 12 females) ( Tables 1,2) .
Study Protocol
The subjects were randomized into either a group starting combined therapy consisting of 20 mg/day atorvastatin and 3 g/day colestimide or a group starting intensive monotherapy with 40 mg/day atorvastatin. Atorvastatin was administered after a meal in the morning and colestimide was administered immediately before meals in the morning and evening. After 16 weeks of treatment, the subjects in each group were immediately switched to the other therapy and treated for another 16 weeks (cross-over). The subjects underwent an examination every 4 weeks that consisted of blood tests and questions about their present condition. Blood samples for lipids and biochemical parameters were collected into plain tubes or tubes containing ethylendiamine tetraacetic 2-sodium (EDTA 2Na) after an overnight fast. Plasma LDL-C, high-density lipoprotein-cholesterol (HDL-C) and triglycerides (TG) were measured. In addition, aspartate aminotransferase (AST), alanine amino- transferase (ALT), creatinine, creatine kinase (CK), blood glucose and blood counts were determined. LDL-C was measured directly using an enzyme method. 19 The endpoints were the plasma LDL-C, HDL-C and TG levels for comparison of the lipid-improving actions in both groups, and the mean levels of each at weeks 12 and 16 of administration of the test drugs were evaluated. Adverse reactions (symptoms and laboratory data) were also compared as an additional endpoint.
Concomitant Drugs, Exercise and Dietary Therapies
The subjects were not allowed to use any drugs that affect serum lipids other than the study drugs at any time during the study. The dosage and administration of drugs taken for other purposes could not be changed during the study regardless of whether or not they affected the serum lipids. Furthermore, no alterations to the exercise and dietary therapy regimens were allowed.
Statistical Analysis
Quantitative data are presented as the mean ± SD. Repeated measures ANOVA with post-hoc Fisher's PLSD was performed to compare continuous variables. It was also used to test the drug-order effect associated with the cross-over study. Categorical variables were assessed by the chi-square test. Associations among continuous variables were tested with simple correlation. Stat View J 5.0 (SAS Institute Inc, Cary, NC, USA) was used for all tests, and p<0.05 was considered a statistically significant difference.
Results

Subjects
Of the 17 subjects who were finally enrolled in the crossover study, 8 were randomized into the preliminary intensive monotherapy group and 9 into the combined therapy group. There were no statistical differences in age, gender or lipid profile between the 2 therapy groups (Tables 1,2) . A total of 2 subjects, 1 from each group (cases #6 and #13 in Table 1 ), dropped out because of an adverse event during administration of a study drug. Consequently, 15 subjects (age: 53.0±13.4 years; 5 males, 10 females) completed the cross-over study. No significant differences were recognized between the 2 therapy groups (Tables 1,2) , and thereafter all comparison of the lipids profile in the present study was performed in these final 15 subjects.
Comparison of LDL-C
The mean LDL-C before administration of 20 mg/day atorvastatin (baseline) was 7.95±1.39 mmol/L (308.2± 53.9 mg/dl). The average of the final 2 doses of 20 mg/day atorvastatin was calculated for comparison. Administration of 20 mg/day atorvastatin resulted in a 36.2% reduction in LDL-C, and the level was maintained at 5.07±1.10 mmol/L (196.5±42.6 mg/dl). Subsequently, LDL-C was maintained at approximately 3.6 mmol/L (140 mg/dl) in both treatment groups: 3.76±0.9 mmol/L (145.6±34.5 mg/dl) in the combined therapy group and 3.81±0.50 mmol/l (147.8± 19.4 mg/dl) in the intensive monotherapy group. LDL-C was significantly decreased in both groups compared with the administration of 20 mg/day atorvastatin (p<0.001 or p<0.001). The percent reductions in LDL-C relative to the value before administration of 20 mg/day atorvastatin were 25.9±12.9% in the combined therapy group and 22.5± 15.5% in the intensive monotherapy group. Therefore, the treatments significantly lowered LDL-C in both groups, with no significant difference between the 2 groups (p=0.858, Fig 1) . The drug-order effect was also compared, but no difference was observed regardless of which therapy was administered first (F=1.047, p=0.383 by repeated measures ANOVA).
Comparison of TG and HDL-C
The baseline TG was 1.27±0.65 mmol/L (112.9± 57.7 mg/dl) with administration of 20 mg/day atorvastatin. Similar levels were maintained with both the combined therapy (1.31±0.83 mmol/L; 116.3±73.7 mg/dl) and the intensive monotherapy (1.20±0.48 mmol/L; 105.9±42.1 mg/dl), and no significant changes were seen between the 2 groups (p=0.336, Fig 2) . Furthermore, no significant changes in the baseline HDL-C (1.48±0.36 mmol/L; 57.5±14.1 mg/dl) with administration of 20 mg/day atorvastatin were observed for the combined therapy (1.52±0.28 mmol/L; 59.0±11.0 mg/dl) and the intensive monotherapy (1.51±0.31 mmol/L; 58.5± 12.1 mg/dl) (p=0.100, Fig 3) .
Adverse Events
Of the 17 subjects who were finally enrolled in the crossover study, 1 who was receiving the intensive monotherapy complained of abdominal discomfort and another who was undergoing the combined therapy had diarrhea and in both cases, the test drugs were withdrawn. These 2 subjects dropped out during their respective first treatments. Compliance was satisfactory for all the other subjects. With regard to liver transaminases, AST was elevated in 1 subject and ALT was elevated in 2, but as the elevations were mild (<100 IU/L) in all 3 subjects and no findings that would be clinically problematic were noted, administration of the test drug was continued. In addition, a mild elevation in CK was seen in 2 subjects, but muscle pain and other symptoms were absent, and hence they continued to participate in the study.
Discussion
In the present study, we demonstrated that combined therapy with atorvastatin and colestimide and intensive monotherapy with atorvastatin were similarly powerful for reducing LDL-C in refractory heterozygous FH. Also, we found that some patients responded better to combined therapy or intensive monotherapy than to the other therapy on the basis of LDL-C reduction or adverse reactions.
Atorvastatin has a more potent cholesterol-lowering action than conventional statins and lowers LDL-C in heterozygous FH patients in a dose-dependent manner. 10 In a previous study in heterozygous FH patients, atorvastatin exhibited a superior cholesterol-lowering action to that of the combinations of simvastatin with fenofibrate or colestyramine. 12 In the Antioxidant Supplementation in Atherosclerosis Prevention study, atorvastatin not only lowered cholesterol in heterozygous FH patients, but also decreased the carotid artery intima -media thickness. 20 Given these findings, subsequent drug treatments for heterozygous FH patients will most likely involve attempts at combining atorvastatin with other lipid-lowering agents.
Anion-exchange resins have been used in the treatment of hyperlipidemia for a long time. In the Lipid Research Clinics-Coronary Primary Prevention Trial and Follow-up Study conducted in the 1980s, anion-exchange resin significantly lowered serum cholesterol, thereby significantly reducing the risk of the onset of CAD. 21 By adsorbing bile acid in the intestinal tract and promoting its evacuation in the feces, anion-exchange resins, which are not adsorbed by the body, lower LDL-C levels in the blood by promoting uptake of cholesterol from the blood to the liver and catabolism to bile acid. 22 Because their mechanism of action differs completely from that of statins, an add-on cholesterol-lowering effect is expected by combining them with statins, and as they are not adsorbed by the body, they can be used safely in combination with statins. As such, it is hoped that they will be effective in refractory cases in which there is insufficient cholesterol reduction with statins alone. 12 Colestimide is a newly developed anion-exchange resin that adsorbs biliary acid more effectively and has a lower incidence of diarrhea, abdominal fullness and other adverse reactions than the conventionally used colestyramine. The results of the current study indicate that it also shows excellent LDL-C lowering as an add-on effect.
An equivalent or higher level of cholesterol management (LDL-C <100 mg/dl (2.6 mmol/L)) as required for patients with a history of CAD is believed to be necessary for heterozygous FH patients. In the present study, LDL-C was lower for the study therapies than for administration of 20 mg/dl atorvastatin (Fig 2) , but only 7 (23%) subjects achieved the guideline targets (LDL-C 100 (2.6), 120 (3.1) or 140 mg/dl (3.6 mmol/L)) for each therapy. The mode of administration, drug combinations and other factors need to be investigated in the future.
If the therapeutic effects of different treatments are the same, the treatment that costs the patient less is likely to be the better choice for the patient. Comparing the daily costs of the different treatments, 40 mg/day atorvastatin cost $6 and the combination of 20 mg/day atorvastatin and 3 g colestimide cost $5 in Japan. Therefore, the combined therapy cost less. In the case of heterozygous FH patients who have to continue drug therapy throughout their entire lives, the significance of choosing a treatment based on cost cannot be underestimated. 23 In addition, regarding adverse events, the test drug was withdrawn from 1 subject in the combined therapy group as a result of diarrhea, but in general the compliance was satisfactory. In biochemical measurements, although mild elevations of AST and ALT were noted, the therapies were continued because these were not considered to be at clinically problematic levels.
Study Limitations
The first one is that examination of individual subjects revealed that each therapy was predominantly more effective in some patients than in others and we did not examine the factors behind these differences because the number of patients was limited. One explanation is differences in body weight. Body weight was associated with the %change of LDL-C by combined therapy (r=-0.395, p=0.148, simple correlation analysis) and by intensive monotherapy (r=-0.137, p=0.634, simple correlation analysis). These results simply suggest that the dose of medicine, especially colestimide, became relatively smaller according to the larger body weight and showed weaker effects. Recently, it was reported that preheparin lipoprotein lipase could discriminate colestimide responders, but other patient characteristics, including body weight, could not. 24 It was also reported that an important clue to discriminating the responder and non-responder to statins was genetic poly-morphisms of apolipoprotein AI gene, estrogen receptor gene and cholesterol 7 -hydroxylase. [25] [26] [27] However, we did not try to distinguish responders and non-responders to colestimide or atorvastatin. This report just suggests that it is necessary to try a number of therapies for heterozygous FH patients and then choose the most effective one in order to lower the cholesterol level of these patients as much as possible. We need further study of the discriminating factors between responders and non-responders.
The second limitation is that other atherosclerosisrelated biochemical parameters were not examined. Inflammatory parameters, such as C-reactive protein, or other markers of pleiotropic effect 28 might be helpful in therapeutic decision making and further studies that include these new parameters are needed.
Clinical Implications and Conclusions
Although the number of subjects in this study was limited and it was more along the lines of a pilot study, there are important implications in terms of drug treatments for heterozygous FH patients. Furthermore, NCEP-ATP III 29 suggested new aggressive reductions in LDL-C in high-risk subjects, even in non-FH populations, because recent population studies [30] [31] [32] have revealed that LDL-C <70 mg/dl is helpful for primary or secondary prevention. These reports proposed the necessity of more effective drug therapy for the difficult target levels. Therefore, the results of our study suggest that combination therapies or intensive monotherapies are applicable not only for FH but also for refractory non-FH patients. In other words, the LDL-C-lowering action of the intensive monotherapy consisting of 40 mg/day atorvastatin and the combined therapy consisting of 20 mg/day atorvastatin plus colestimide was equivalent when all the subjects were compared, but one or the other was usually superior in individual cases, indicating the need for adjusting the drug combinations and doses. Given its mechanism of action and high safety profile, we consider that it is worth giving colestimide a try in combination with a statin.
